Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and

Peter Lindgren1, Bengt Jönsson, Alberto Redaelli

  • 1Stockholm Health Economics Consulting, Uppsala, Sweden. peter.l@healtheconomics.se

Pharmacoeconomics
|March 13, 2002
PubMed
Abstract